News | May 12, 2008

Laser Ablation System Assists Removal of 975 Cardiac Leads

May 13, 2008 – Spectranetics’ excimer laser sheath safely and effectively assists removal of pacing and defibrillator leads, according to the study, “Large, Single-catheter, Single-operator Experience with Transvenous Lead Extraction: Outcomes and Changing Indications,” featured in the April issue of HeartRhythm.

The study represents a seven year retrospective analysis of data from 498 lead extraction procedures involving 975 leads. The conclusion demonstrates safe extraction of leads successfully removed with laser assistance.

The Spectranetics Laser Sheath (SLS II) use cool ultraviolet light to ablate scar tissue that holds problematic leads in place. A circle of fibers that emit pulses of energy travel over the cardiac lead towards the tip to dissolve scar tissue that binds the lead to the body. Once the scar tissue is dissolved, the lead can be safely removed. Spectranetics’ Lead Locking Device (LLD) technology can also be used to assist removal by creating secure traction during procedures that may or may not require laser assistance.

The retrospective study at Brigham and Women’s Hospital in Boston was designed to examine indications, outcomes and complications associated with transvenous lead extraction. Dr. Laurence Epstein, Chief of Cardiac Arrhythmia Services at Brigham and Women’s Hospital acted as the single-operator in the study handling all 498 lead extraction procedures throughout the seven year period. The study showed a success rate of over 97 percent with only two major complications, and no deaths. These two major complications out of 498 procedures resulted in a major complication rate of only 0.4 percent. The published article also highlights concerns surrounding existing formal recommendations for lead removal given the technologies available to assist the process. The article notes that “the rate of complications from abandoned leads reported in one study was as low as 5.5 percent, which still is higher than the complication rate from extraction.”

“We were interested in reviewing our outcomes, at a high volume center with an experienced operator,” said Dr. Epstein. “Historically the indications for lead extraction have been tempered by the risks, real and perceived, associated with the procedure. This study demonstrates that transvenous lead extraction can be performed safely and effectively in a wider population of patients.” Dr. Epstein further describes his strategy, explaining, “Hopefully, this will reduce the number of patients subjected to open heart procedures and the risks and complications of abandoned leads. However, this is not an endorsement for the performance of extraction, more widely, in inexperienced hands. Excellent results are achieved through careful preparation, planning and experience.”

For more information: www.spectranetics.com

Related Content

Stereotaxis Receives Regulatory Approval of e-Contact Module in Canada
Technology | Ablation Systems| December 08, 2017
December 7, 2017 — Stereotaxis Inc.
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Abbott Announces CE Mark for New Cardiac Ablation Catheter
News | Ablation Systems| May 10, 2017
Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems| February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
CardioFocus, HeartLight Excalibur Balloon, 22nd Annual AF Symposium, atrial fibrillation, initial clinical evaluation
News | Ablation Systems| January 25, 2017
CardioFocus Inc. recently announced the initial clinical evaluation of the HeartLight Excalibur Balloon, a next-...
catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association
News | Ablation Systems| November 14, 2016
Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of...
Overlay Init